Navigation Links
Antibody Technologies and Attrition Rates -- an industry analysis 2013
Date:3/27/2013

NEW YORK, March 27, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Antibody Technologies and Attrition Rates – an industry analysis 2013

http://www.reportlinker.com/p01154426/Antibody-Technologies-and-Attrition-Rates-–-an-industry-analysis-2013.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical

Product Description

The report "Antibody Technologies and Attrition Rates – an industry analysis 2013" is based on the identification of the antibody generation technologies of 504 naked antibodies in clinical or market stages. Information was retrieved from scientific and corporate publications as well as from patent and legal literature. The report provides descriptive statistics of the 504 naked antibodies and their status during the study period of January 1, 2013 to February 28, 2013. The antibodies are categorized as active during the study period or discontinued during or before the study period. Attrition rates were calculated across a number of variables.

Descriptive statistics of the 504 naked antibodies include the following variables:

  • Unique antibody identifiers (drug codes; generic name; brand name)
  • Antibody format (full length, Fab, scFv, VH/VL, nanobody, bispecific, cocktail/polyclonal)
  • In vitro antibody generation technologies (display technologies from CAT, Dyax, Morphosys, BioInvent, Domantis, Genentech, others)
  • In vivo antibody generation technologies (chimeric, primatized, nanobodies, deimmunized, human engineered, humaneered, humanized, XenoMouse,
  • HuMab mouse, KM mouse, VelocImmune mouse, human B-cell derived)
  • Animal species of parental wild-type antibody (mouse, rat, rabbit, hamster, cynomolgus monkey, camelid)
  • Antibody status (active/discontinued)
  • Year of failure
  • Reason for failure (efficacy, pharmacokinetics/ADME; safety; technical, business, next generation, inactivity)
  • Target
  • Immunoglobulin class and IgG isotype
  • Highest phase
  • Therapeutic area of lead indication
  • Companies (developer, licensor/originator)

An Antibody Data Sheet was prepared for each unique antibody containing the retrieved information and the source of information in the form of a scientific reference or a hyperlink leading to the website from which the information was obtained.

The analysis essentially evaluated the question whether there are differences in clinical attrition rates between in vitro and in vivo antibody generation technologies as well as within the different in vitro and in antibody generation technologies. Attrition rate was defined as the percentage of failed antibodies of all active and inactive antibodies.

Benefits from the data and the analysis:

  • Understand the historical and present state of the art use of antibody technologies;
  • Learn the success rate of each antibody generation technology;
  • Understand the reasons for failure of antibodies in clinical development;
  • Appreciate the relative value of generic and of IP protected antibody technologies;
  • Know which antibody technologies are using your competitors;
  • Know the preferred antibody formats, IgG isotypes, development indications, parental wild-type animal species.
  • Learn the influence of the target for the success rate of the selected antibody technology.

Table of Contents

1 Executive Summary and Discussion

2 Introduction 3 Methodology 4 Results 4.1 Use of antibody technologies

4.2 Attrition rates

4.3 Reasons for failure

4.4 Antibody generation technologies and targets

4.5 Antibody technologies and antibody formats

4.6 Parental animal species of in vivo generated antibodies

4.7 Immunoglobulin class and isotype vs. antibody technology

4.8 Antibody technology and therapeutic areas

4.9 Attrition rates of antibodies in therapeutic areas

4.10 Benchmark analysis: big pharma and biotech antibody technology preferences and attrition rates

5 Tables Table 1 Overall attrition rate of in vitro generated antibodies

Table 2 Overall attrition rate of in vivo generated antibodies

Table 3 Highest phase of active antibodies generated by in vitro technologies

Table 4 Highest phase of active antibodies generated by in vivo technologies

Table 5 Year of antibody failure for in vitro generated antibodies

Table 6 Year of antibody failure for in vivo generated antibodies

Table 7 Attrition rate of in vitro generated antibodies in the period 2006-2013

Table 8 Attrition rate of in vivo generated antibodies in the period 2006-2013

Table 9 Highest phase of failed antibodies generated by in vitro technologies

Table 10 Highest phase of failed antibodies generated by in vivo technologies

Tables 11 Reasons for failure of antibodies generated by in vitro technologies

Tables 12 Reasons for failure of antibodies generated by in vivo technologies

Table 13 Reasons for failure of humanized antibodies per phase

Tables 14 Targets of failed in vitro generated antibodies per technology

Tables 15 Targets vs. in vitro and in vivo antibody generation technologies

Tables 16 Transgenic mouse antibodies and targets

Table 17 Antibody technologies and antibody formats

Table 18 Parental animal species of in vivo generated antibodies

Table 19 Immunoglobulin class and isotype vs antibody technology

Table 20 In vitro antibody technology and therapeutic areas

Table 21 In vivo antibody technology and therapeutic areas

Table 22 Failed antibodies from in vitro technologies vs therapeutic areas

Table 23 Failed antibodies from in vivo technologies vs therapeutic areas

Table 24 Roche (Genentech(Chugai) use of antibody technologies vs attrition rates

Table 25 AstraZeneca (MedImmune/CAT) use of antibody technologies vs attrition rates

Table 26 Amgen use of antibody technologies vs attrition rates

Table 27 Lilly (ImClone) use of antibody technologies vs attrition rates

Table 28 Pfizer (Wyeth) use of antibody technologies vs attrition rates

Table 29 Novartis use of antibody technologies vs attrition rates

Table 30 GlaxoSmithKline (HGS) use of antibody technologies vs attrition rates

Table 31 Sanofi (Genzyme) use of antibody technologies vs attrition rates

Table 32 Bristol-Myers Squibb (Medarex) use of antibody technologies vs attrition rates

Table 33 Biogen Idec use of antibody technologies vs attrition rates

Table 34 Janssen (Centocor/J&J) use of antibody technologies vs attrition rates

Table 35 AbbVie (Abbott) use of antibody technologies vs attrition rates

Table 36 Kyowa Hakko Kirin Pharma use of antibody technologies vs attrition rates

Table 37 Merck (Schering-Plough) use of antibody technologies vs attrition rates

Table 38 UCB (Celltech) use of antibody technologies vs attrition rates

Table 39 Eisai (Morphotek) use of antibody technologies vs attrition rates

Table 40 Novo Nordisk use of antibody technologies vs attrition rates

Table 41 Ranking list of Big Pharma & Biotech companies and overall antibody attrition rates

Table 42 Ranking list of Big Pharma & Biotech companies and in vitro antibody attrition rates

Table 43 Ranking list of Big Pharma & Biotech companies and in vivo antibody attrition rates

Table 44 Ranking list of Big Pharma & Biotech companies and in vivo antibody preference rate

Table 45 Big Pharma & Biotech companies and preferred in vivo antibody technologies: humanization vs. transgenic mice

6 Addendum: Antibody Data Sheets

To order this report:

Biopharmaceutical Industry: Antibody Technologies and Attrition Rates – an industry analysis 2013

Contact Clare: clare@reportlinker.com
US:(339) 368 6001
Intl:+1 339 368 6001


'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. iBio Adds New Therapeutic Antibody to Its Pipeline
2. Glenmark Announces a New Discovery and the Initiation of IND Enabling Studies of a Novel Monoclonal Antibody Targeting OX40
3. Monoclonal Antibody Partnering Terms & Agreements Discussed in New Report Now Available at MarketPublishers.com
4. GeneTex Launches New Antibody Against Phosphorylated Histone H3 for Epigenetics Research
5. NKT Therapeutics Presents Data on Potential Antibody Treatment for Sickle Cell Disease
6. Ebola antibody treatment, produced in plants, protects monkeys from lethal disease
7. Preclinical data shows 100 percent prevention and treatment of influenza with engineered human antibody
8. Oncobiologics, Inc. Announces a Collaboration Agreement with XOMA Corporation to Utilize XOMAs Fully Human Antibody Libraries for Their Discovery Platform
9. Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
10. RayBiotech, Inc. and the University of Oslo Enter into Antibody Array Services Collaboration
11. Sinovac to Present at 55th Annual BioPharma China Convention 2012 - Vaccine & Antibody Focus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... February 08, 2016 , ... Franz Inc. ... Graph Database technology, today announced the availability of AllegroGraph 6, the leading Semantic ... Cloudera Certified Technology Program (CCPT). AllegroGraph is the first Semantic Graph ...
(Date:2/8/2016)... has an active R&D program for the development ... the Group has a unique research and development center in ... developing Bio Control products. Stockton has ... and regulatory guidelines, and is active in more than 35 ... Stockton,s flagship product Timorex Gold ® ...
(Date:2/8/2016)... 2016 --> ... "Company"), the ultra-rapid Point-Of-Care (POC) molecular diagnostics company, today announces ... trachomatis (CT) test to be launched on the Company,s io® ... the CT test is now cleared for sale within the ... The launch of the io® CT test signals a new ...
(Date:2/6/2016)... ... February 06, 2016 , ... Contact:, ... Center for Excellence in Education Sponsors Teacher Training Program , Bite of Science ... – The Center for Excellence in Education (CEE) will sponsor a Bite of ...
Breaking Biology Technology:
(Date:1/20/2016)... A market that just keeps on growing. ... explosion in genomics knowledge. Learn all about it in ... of dynamic trends are pushing market growth and company ... pharmacogenomics - pathogen evolution - next generation sequencing - ... understanding of the role of genetic material in Disease ...
(Date:1/18/2016)... Calif. , Jan. 18, 2016  Extenua ... software that simplifies the use and access of ... and go-to-market partnership with American Cyber.  ... brings extensive experience leading transformational C4ISR and Cyber ... and integrating the latest proven technology solutions," said ...
(Date:1/13/2016)... DUBLIN , January 13, 2016 ... has announced the addition of the  ... - Estimation & Forecast (2015-2020)" ... http://www.researchandmarkets.com/research/7h6hnn/india_biometrics ) has announced the ... & Identification Market - Estimation & ...
Breaking Biology News(10 mins):